The Technical Analyst
Modus Therapeutics [MODTX.ST]
Exchange: STO Sector: Healthcare Industry: Biotechnology
Modus Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals
-4.17% SEK1.035
America/New_York / 17 mai 2024 @ 10:48
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 37.20 mill |
| EPS: | -1.010 |
| P/E: | -1.020 |
| Earnings Date: | N/A |
| SharesOutstanding: | 35.94 mill |
| Avg Daily Volume: | 0.0253 mill |
| RATING 2024-05-17 |
|---|
| C+ |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.020 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.00x |
| Company: PE -1.020 | industry: PE 491.84 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
SEK0.530 (-48.76%) SEK-0.505 |
| Date: 2024-05-18 |
| Expected Trading Range (DAY) |
|---|
|
SEK 0.962 - 1.098 ( +/- 6.60%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - SEK1.030
Forecast 2: 16:00 - SEK1.030
Forecast 3: 16:00 - SEK1.030
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | SEK1.035 (-4.17% ) |
| Volume | 0.0085 mill |
| Avg. Vol. | 0.0253 mill |
| % of Avg. Vol | 33.70 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For MODTX.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
MODTX.ST
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.